Fabric Genomics & Nubank

Fabric Genomics: Fabric Genomics was acquired by Nubank with promises of revenue growth and efficiencies, but its failure to meet these expectations led to a $31.2 million impairment charge and is central to the securities lawsuit.

Nubank: Nubank is the defendant in a securities class action lawsuit due to alleged misleading statements regarding its Fabric Genomics acquisition, which led to a significant stock price collapse and financial write-offs.

Fabric Genomics: Fabric Genomics was acquired by Nubank for $33.2 million, but its performance was allegedly misrepresented, leading to a $31.2 million impairment charge for Nubank and contributing significantly to its net loss.

Nubank: Nubank is the defendant in a class action lawsuit alleging securities fraud due to misleading statements about its business, operations, and prospects, particularly regarding the acquisition of Fabric Genomics and its average reimbursement rates. This has led to a significant drop in its stock price and negative investor sentiment.

Fabric Genomics: Fabric Genomics was acquired by Nubank Corp., and its alleged viability problems are central to the class action lawsuit, leading to an impairment loss for GeneDx.

Nubank: Nubank Corp. is the primary defendant in a class action lawsuit alleging securities fraud due to misleading statements regarding its acquisition of Fabric Genomics, which led to a significant drop in its stock price and an impairment loss.